Potential possible renal benefits, particularly in diabetics with chronic kidney disease (CKD) and albuminuria, include a decrease in albuminuria, reduction of the decline of estimated glomerular filtration rate (eGFR) or progression to end-stage renal disease, lower death rates from renal causes, and extended time to initiation of renal replacement therapy [3]. Currently, FDA approved and indicated for HFrEF, the rise to fame of SGLT2 inhibitors did not happen overnight. Here, SLC5A2 is linked to chronic kidney disease.